Heart Disease of the Small Arteries in Women
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Women suffer disproportionately than men from coronary heart disease in the small vessels (arterioles) compared to the large vessels (arteries). This results in delays in diagnosis, missed opportunities for treatment, and likely contributes to the increased death rate from coronary heart disease in women compared to men. Current testing for small vessel disease is invasive in the cardiac catheterization laboratory and is not performed routinely. Accordingly, women with this condition are routinely either falsely reassured, or misdiagnosed as another non-cardiac condition.
New imaging and noninvasive technology exists that may improve this situation. Measurement of endothelial function, using non-invasive tonometry testing can detect the abnormality most associated with coronary heart disease, endothelial dysfunction. Imaging techniques such as cardiac magnetic resonance imaging can now show the subendocardial layer of the heart, where the small vessel abnormality exists. These techniques have not been tested to determine if they can be used to diagnose and treat the small vessel coronary heart disease condition.
40 women undergoing coronary angiography with non-obstructive coronary artery disease will be enrolled. They will receive invasive provocative acetylcholine testing in the cardiac catheterization laboratory, followed by noninvasive Peripheral Artery Tonometry (PAT)testing, and cardiac magnetic resonance testing. Correlation analyses will be analyzed with regard to the predictive value of the noninvasive testing for the outcome of small vessel disease by the invasive acetylcholine testing. The data from this study will be pilot data for a larger prospective study. These studies an important step toward better understanding, and safer diagnosis of the coronary heart disease that is prevalent in over 9 million American women today.
| Condition | Intervention | Phase |
|---|---|---|
|
Heart Disease |
Procedure: noninvasive tests |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Heart Disease of the Small Arteries in Women |
- noninvasive Peripheral Artery Tonometry (PAT) testing and Cardiac Magnetic Resonance (CMR) imaging for the outcome of coronary endothelial dysfunction [ Time Frame: 120 minutes ] [ Designated as safety issue: No ]
- clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing [ Time Frame: 60 minutes ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 634 |
| Study Start Date: | November 2005 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Single Arm |
Procedure: noninvasive tests
clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women with signs and symptoms of myocardial ischemia (chest pain, abnormal stress testing, abnormal noninvasive testing) in the absence of obstructive coronary artery disease (<50% luminal obstruction in one or more coronary arteries on angiography).
Exclusion Criteria:
- Contraindications to angiography and invasive coronary function testing with acetylcholine.
- Contraindications to withholding nitrates, calcium channel agents, ACE/ARB agents for 48 hours prior to testing.
- Life expectancy less than 6 months
Contacts and Locations| Contact: Chrisandra Shufelt, MD | 310-423-9680 | ShufeltC@cshs.org |
| Contact: Ying Mou, PhD | 310-248-7669 | Ying.Mou@cshs.org |
| United States, California | |
| Cedars-Sinai Women's Heart Center | Recruiting |
| Los Angeles, California, United States, 90048 | |
| Contact: Ying Mou, PhD 310-248-7669 Ying.Mou@cshs.org | |
| Principal Investigator: Noel Bairey-Merz, MD | |
| Sub-Investigator: Saible Kar, MD | |
| Sub-Investigator: Raj Makkar, MD | |
| Sub-Investigator: Dan Berman, MD | |
| Sub-Investigator: Leslee Shaw, MD | |
| Sub-Investigator: Louise Thompson, MBChB | |
| Sub-Investigator: Rola Saouf, MD | |
| Principal Investigator: | Noel Bairey-Merz, MD | Cedars-Sinai Medical Center |
More Information
No publications provided
| Responsible Party: | Noel Bairey Merz, Director, Cedars-Sinai Medical Center |
| ClinicalTrials.gov Identifier: | NCT00573027 History of Changes |
| Other Study ID Numbers: | IRB 8221 |
| Study First Received: | December 12, 2007 |
| Last Updated: | May 6, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Cedars-Sinai Medical Center:
|
microvascular dysfunction Microvascular |
Additional relevant MeSH terms:
|
Heart Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013